7WKX

IL-17A in complex with the humanized antibody HB0017

Summary for 7WKX

• Entry DOI: 10.2210/pdb7wkx/pdb
• Descriptor: Heavy chain of HB0017 Fab, Light chain of HB0017 Fab, Interleukin-17A, ... (6 entities in total)
• Functional Keywords: hb0017, il17a, monoclonal antibody, complex, cytokine
• Biological source: Homo sapiens; More
• Total number of polymer chains: 6
• Total formula weight: 130062.77

Authors

Xu, J.,Zhu, X.,He, Y. (deposition date: 2022-01-12, release date: 2022-03-23, Last modification date: 2024-10-16)

Primary citation

Xu, J.G.,Jia, H.,Chen, S.,Xu, J.,Zhan, Y.,Yu, H.,Wang, W.,Kang, X.,Cui, X.,Feng, Y.,Chen, X.,Xu, W.,Pan, X.,Wei, X.,Li, H.,Wang, Y.,Xia, S.,Liu, X.,Yang, L.,He, Y.,Zhu, X.
Structural and functional insights into a novel pre-clinical-stage antibody targeting IL-17A for treatment of autoimmune diseases.
Int.J.Biol.Macromol., 202:529-538, 2022

PubMed Abstract: The pro-inflammatory cytokine interleukin-17A (IL-17A) is a key driver of multiple inflammatory and immune disorders. Therapeutic antibodies targeting IL-17A have been proven effective in treating patients with these diseases; however, large variations in clinical outcomes have been observed with different antibodies. In this study, we developed HB0017, a novel monoclonal antibody that targets human IL-17A. HB0017 specifically and strongly bound to human, cynomolgus monkey, and mouse IL-17A at the physiological interface with the IL-17A receptor. In human and monkey cells, HB0017 potently antagonized the functions of IL-17A through competitive binding. HB0017 functioned equivalently to that of clinically approved antibodies in terms of therapeutic efficacy for inflammatory disorders and psoriasis in a mouse model. The results indicate that HB0017 may be an alternative biological therapy for treating patients with inflammation and autoimmune diseases.

PubMed: 35066019
DOI: 10.1016/j.ijbiomac.2022.01.119

Experimental method

X-RAY DIFFRACTION (2.81 Å)